TARGETING O-ACETYLATED GD2 GANGLIOSIDE AS A NEW THERAPEUTIC AND DIAGNOSTIC STRATEGY FOR CANCER STEM CELLS CANCER

摘要

The present disclosure relates to an antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer. The present disclosure further concern a pharmaceutical composition comprising said antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, said method comprising administering said antibody to said patient. The present disclosure also relates to a method for diagnosing a CSC and to the use of the 0-acetylated-GD2 ganglioside as a biomarker of CSC cancer. Finally, the disclosure relates to a method for predicting the response of a subject affected with CSC cancer to a treatment with an antibody or a composition of the invention.